CMO of ONCY buys 12,132 shares at $0.83; 8 other insiders bought within 14 days—coordinated pattern
Heineman Thomas Charles, Chief Medical Officer of Oncolytics Biotech, purchased 12,132 shares at $0.83, expanding his stake by 4.5% to 282,818 shares. The transaction occurred at a notable discount to the current price of $1.06 and well below the 52-week high of $1.42. The timing is material because this purchase is part of a cluster pattern: 8 other insiders also bought within the past 14 days. Cluster buying by multiple executives can signal shared conviction about near-term value, though it may also reflect access to material information or coordinated capital deployment decisions. The stock remains -25.4% from its 52-week high despite recent upward momentum (+1.9% over 90 days), warranting investor attention to underlying catalysts and insider motive.